Price
$2.28
Increased by +2.70%
Dollar Volume
1.44 M
ADR%
8.48
Earnings Report Date (estimate)
Feb 28, 23 (-0.37)
Market Cap.
44.92 M
Shares Float
11.31 M
Shares Outstanding
19.70 M
Beta
0.68
Price / Earnings
-1.64
BPR
214.86
20D Range
2.09 3.18
50D Range
1.13 4.56
200D Range
1.11 4.56
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.31
Decreased by -34.78%
-0.68
Increased by +54.41%
Aug 15, 22 -0.17
Increased by +26.09%
-0.57
Increased by +70.18%
May 16, 22 -0.64
Decreased by -481.82%
-0.41
Decreased by -56.10%
Mar 2, 22 -0.31
Increased by +38.00%
-0.01
Decreased by -3.00 K%
Nov 19, 21 -0.23
Increased by +54.90%
-0.28
Increased by +17.86%
Aug 10, 21 -0.23
Increased by +58.93%
-0.36
Increased by +36.11%
May 17, 21 -0.11
Increased by +77.55%
-0.44
Increased by +75.00%
Mar 1, 21 -0.50
Increased by +1.96%
-0.41
Decreased by -21.95%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-5.01 M
Decreased by -52.98%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-2.67 M
Increased by +17.36%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-9.18 M
Decreased by -506.61%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 360.00 K
Increased by +N/A%
-4.42 M
Increased by +29.13%
Decreased by -1.23 K%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-3.27 M
Increased by +44.79%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-3.23 M
Increased by +44.08%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 4.00 M
Increased by +N/A%
-1.51 M
Increased by +69.42%
Decreased by -37.85%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-6.24 M
Decreased by -20.97%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.